Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

McGill University

$17,500.00

Further Characterization of the Dolutegravir Resistance Mutation R263K: Combinations with Primary INSTI Resistance Mutations and Possible Compensatory Mechanisms

FY 2013-14

Summary
It is estimated that over 34 million people are currently infected with human immunodeficiency virus (HIV) worldwide. Although antiretroviral therapy has been lifesaving for many HIV-positive individuals, drug resistance threatens its long-term efficacy. A newly approved class of drugs, termed the integrase strand transfer inhibitors (INSTIs), has been an important addition to the antiretroviral arsenal over the last six years. Integrase is a HIV protein that is essential for the integration of viral DNA into the host’s genome, which is a crucial step in the HIV lifecycle. Without integration, HIV would not be able to replicate its genome or spread from cell to cell within a person, or from person to person within a population. Thus, integrase is an attractive target for anti-HIV medications. Though HIV has been able to develop resistance to the currently available INSTIs raltegravir (RAL) and elvitegravir (EVG), it has yet to do so to the newly developed INSTI dolutegravir (DTG) in treated patients. However, we have been able to artificially make the virus resistant to this drug through an amino acid change at position 263 (R263K); this mutation causes the amino acid arginine (R) to be replaced by the amino acid lysine (K) at position 263. This mutation has also recently been identified in patients receiving DTG treatment, although it was concluded that R263K accounted for less than a two-fold increase in resistance under these circumstances. This mutation also impairs the activity of the integrase protein, as do the primary resistance mutations identified for RAL and EVG. A lower activity of integrase means a decrease in HIV infectivity and fitness, however the advantage of resistance outweighs the cost of reduced activity in the presence of drug and hence this mutation is favoured. This led us to question if this would also be the case if R263K and other INSTI resistance mutations were combined in a single virus. To test this hypothesis, I will generate multiple versions of the integrase protein with R263K in combination with the previously identified INSTI resistance mutations. These proteins can be safely expressed from a bacterial source, and then assayed biochemically for their activity. I will then generate competent HIV virus with the same mutations and analyze the ability of the viruses to infect human cells in culture. This work has the potential to greatly impact clinical practices and the lives of those living with HIV/AIDS. Drug resistance has been established for every class of antiretroviral drugs to date, and this threatens patient outlook and the development of a cure. Dolutegravir is a very promising addition to the fight against HIV, but not enough characterization of the mutational pathways in response to DTG treatment has been undertaken. At the end of this project, we will be able to definitively answer some fundamental questions about DTG, the fitness trade-offs of HIV INSTI resistance, and the cooperation of distinct mechanisms of resistance. If the R263K mutation cannot be combined with other resistance mutations due to the additive decrease in integrase activity, along with the knowledge that DTG has yet to select for any primary resistance mutations in patients, would suggest that this drug could be the beginning of the end of HIV drug resistance, and hence the AIDS epidemic. The outcomes of this research will have a direct effect on patient care for HIV-positive individuals.
Program
Master's Award: Canada Graduate Scholarships
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
311953
Name
Anstett Kaitlin
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Further Characterization of the Dolutegravir Resistance Mutation R263K: Combinations with Primary INSTI Resistance Mutations and Possible Compensatory Mechanisms
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Biochemistry; Dolutegravir; Drug Resistance; Evolution; Fitness Tradeoffs; Hiv/Aids; Integrase; Integrase Strand Transfer Inhibitors; Molecular Biology; Resistance Mutations
Abstract
It is estimated that over 34 million people are currently infected with human immunodeficiency virus (HIV) worldwide. Although antiretroviral therapy has been lifesaving for many HIV-positive individuals, drug resistance threatens its long-term efficacy. A newly approved class of drugs, termed the integrase strand transfer inhibitors (INSTIs), has been an important addition to the antiretroviral arsenal over the last six years. Integrase is a HIV protein that is essential for the integration of viral DNA into the host’s genome, which is a crucial step in the HIV lifecycle. Without integration, HIV would not be able to replicate its genome or spread from cell to cell within a person, or from person to person within a population. Thus, integrase is an attractive target for anti-HIV medications. Though HIV has been able to develop resistance to the currently available INSTIs raltegravir (RAL) and elvitegravir (EVG), it has yet to do so to the newly developed INSTI dolutegravir (DTG) in treated patients. However, we have been able to artificially make the virus resistant to this drug through an amino acid change at position 263 (R263K); this mutation causes the amino acid arginine (R) to be replaced by the amino acid lysine (K) at position 263. This mutation has also recently been identified in patients receiving DTG treatment, although it was concluded that R263K accounted for less than a two-fold increase in resistance under these circumstances. This mutation also impairs the activity of the integrase protein, as do the primary resistance mutations identified for RAL and EVG. A lower activity of integrase means a decrease in HIV infectivity and fitness, however the advantage of resistance outweighs the cost of reduced activity in the presence of drug and hence this mutation is favoured. This led us to question if this would also be the case if R263K and other INSTI resistance mutations were combined in a single virus. To test this hypothesis, I will generate multiple versions of the integrase protein with R263K in combination with the previously identified INSTI resistance mutations. These proteins can be safely expressed from a bacterial source, and then assayed biochemically for their activity. I will then generate competent HIV virus with the same mutations and analyze the ability of the viruses to infect human cells in culture. This work has the potential to greatly impact clinical practices and the lives of those living with HIV/AIDS. Drug resistance has been established for every class of antiretroviral drugs to date, and this threatens patient outlook and the development of a cure. Dolutegravir is a very promising addition to the fight against HIV, but not enough characterization of the mutational pathways in response to DTG treatment has been undertaken. At the end of this project, we will be able to definitively answer some fundamental questions about DTG, the fitness trade-offs of HIV INSTI resistance, and the cooperation of distinct mechanisms of resistance. If the R263K mutation cannot be combined with other resistance mutations due to the additive decrease in integrase activity, along with the knowledge that DTG has yet to select for any primary resistance mutations in patients, would suggest that this drug could be the beginning of the end of HIV drug resistance, and hence the AIDS epidemic. The outcomes of this research will have a direct effect on patient care for HIV-positive individuals.
Competitiondate
201312
Approvedterm2
1 yr 0 mth
Pinamesdelim
Anstett, Kaitlin
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~